Comparison of HDAC inhibitors in clinical development
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2013/05/14
-
Indian UGC (journal)
-
Refrences50
-
Citations149
-
Thomas Aagaard Rasmussen
-
Ole Schmeltz Søgaard
-
Christel Brinkmann
-
Fiona Wightman
-
Sharon R. Lewin
-
Jesper Melchjorsen
-
Charles Dinarello
-
Lars Østergaard
-
Martin Tolstrup
Cite
Rasmussen, Thomas Aagaard, et al. “Comparison of HDAC Inhibitors in Clinical Development”. Human Vaccines &Amp; Immunotherapeutics, vol. 9, no. 5, 2013, pp. 993-1001, https://doi.org/10.4161/hv.23800.
Rasmussen, T. A., Søgaard, O. S., Brinkmann, C., Wightman, F., Lewin, S. R., Melchjorsen, J., Dinarello, C., Østergaard, L., & Tolstrup, M. (2013). Comparison of HDAC inhibitors in clinical development. Human Vaccines &Amp; Immunotherapeutics, 9(5), 993-1001. https://doi.org/10.4161/hv.23800
Rasmussen TA, Søgaard OS, Brinkmann C, Wightman F, Lewin SR, Melchjorsen J, et al. Comparison of HDAC inhibitors in clinical development. Human Vaccines & Immunotherapeutics. 2013;9(5):993-1001.
Journal Categories
Medicine
Internal medicine
Specialties of internal medicine
Immunologic diseases
Allergy
Medicine
Therapeutics
Pharmacology
Technology
Chemical technology
Biotechnology
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. | The EMBO Journal |
| 415 | 1996 |
| 10.1074/jbc.M511773200 | ||||
| NF-κB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation | 346 | 2005 | ||
| 10.1128/JVI.74.15.6790-6799.2000 | ||||
Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells | Retrovirology |
| 77 | 2011 |
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-α2a | Cell |
| 1 | 2024 |
| Effective and targeted latency reversal in CD4 + T cells from individuals on long term combined antiretroviral therapy initiated during chronic HIV-1 infection | Emerging Microbes & Infections |
| 2024 | |
| Highlights of the HIV cure session, 19th European AIDS Clinical Society (EACS) Conference, 18-21 October 2023, Warsaw, Poland | Journal of Virus Eradication |
| 2023 | |
Potent latency reversal by Tat RNA-containing nanoparticle enables multi-omic analysis of the HIV-1 reservoir | Nature Communications |
| 4 | 2023 |
| Eliminating the HIV tissue reservoir: current strategies and challenges | Infectious Diseases |
| 2023 |
Citations Analysis
The category
Science: Microbiology 65
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4+ T Cells from Aviremic Patients and was published in 2013. The most recent citation comes from a 2024 study titled Effective and targeted latency reversal in CD4
+
T cells from individuals on long term combined antiretroviral therapy initiated during chronic HIV-1 infection. This article reached its peak citation in 2016, with 32 citations. It has been cited in 80 different journals, 30% of which are open access. Among related journals, the PLOS Pathogens cited this research the most, with 10 citations. The chart below illustrates the annual citation trends for this article.